Kenvue Inc. Advanced Charts | KVUE
This article provides detailed financial data and charting information for Kenvue Inc. (KVUE), including stock performance, analyst ratings, market capitalization, dividend yield, and short interest. It also offers an overview of Kenvue as a consumer health company with brands like Aveeno and Tylenol, operating in Self Care, Skin Health and Beauty, and Essential Health segments.
Kenvue stock enters a leadership transition before deal close
Kenvue is undergoing a leadership transition in anticipation of its planned acquisition by Kimberly-Clark, with the deal expected to close in Q4 2026. The company reported a 3.0% increase in Q2 2026 net sales to $3.955 billion and a 9% rise in diluted EPS to $0.24. Analysts currently hold a "Hold" consensus for Kenvue, with an average 12-month price target of $19.27, suggesting a 12.0% upside from its October 2nd price of $17.20.
Kenvue Inc. Stock Grades | KVUE
This article provides a stock overview for Kenvue Inc. (KVUE), including analyst ratings, key financial data such as market value, EPS, P/E ratio, and dividend yield, and details about the company's consumer health products and segments. The average analyst price target is $19.30, with an average score of "Sell," while the stock grader rating is N/A.
Zacks flags Kimberly-Clark deal risks for Kenvue stock
Zacks has flagged deal-execution risks for Kenvue as its planned combination with Kimberly-Clark advances. The transaction, expected to close in Q4 2026, has led Kenvue to withhold forward-looking guidance, making quarterly execution and closing conditions key variables. While sales and earnings per share increased, profitability was pressured, and the stock remains below its yearly high, emphasizing the transaction's importance for investors.
Kenvue (KVUE) Stock Still Appears 41% Undervalued On Cash Flow
Kenvue (KVUE) stock, despite a 16.1% gain over the past year, is still considered 41% undervalued based on its discounted cash flow (DCF) model. The company's strong free cash flow and analyst projections for continued growth suggest an intrinsic value substantially higher than its current share price of US$17.22. Investors are encouraged to look beyond short-term returns and consider the company's underlying cash generation capabilities and strategic initiatives like its $2.1 billion EBITDA synergy program.
Kimberly-Clark announces executive transitions
Kimberly-Clark announced executive changes as it prepares for its acquisition of Kenvue Inc. Russ Torres, President and COO, will depart for a CEO role elsewhere, while Carlos De Jesus will become President, North America, and Leonardo Curado will lead the EMEA segment. These transitions are part of the ongoing integration planning for the combined company, expected to close in Q4 2026.
Keurig Dr Pepper Taps New Head for Global Coffee Co., Russ Torres
Keurig Dr Pepper (KDP) has appointed Russ Torres, previously Kimberly-Clark's President and COO, to lead its new global coffee business, Global Coffee Co., ahead of a planned corporate split in early 2027. Torres will oversee the integration of KDP's existing coffee operations with JDE Peet’s, with the coffee company projected to generate $16 billion in annual revenue. This appointment follows two previous executive leadership changes for the coffee unit since the JDE Peet’s acquisition announcement in August 2025.
Kimberly-Clark Reshapes Leadership Ahead of Kenvue Acquisition
Kimberly-Clark is restructuring its executive leadership in anticipation of its acquisition of Kenvue Inc., appointing new leaders for its North America and EMEA businesses. This move comes as President and Chief Operating Officer Russ Torres departs for an external CEO role, with his responsibilities for integration planning being reallocated. The changes aim to optimize the combined company's operations and capitalize on growth opportunities in consumer health and personal care.
Keurig Dr Pepper names Kimberly-Clark's Russ Torres as coffee spinoff CEO
Keurig Dr Pepper has appointed Russ Torres, currently President and COO of Kimberly-Clark, as the CEO of its planned coffee spinoff, Global Coffee Co. Torres will join Keurig Dr Pepper on November 3 to lead the coffee operating unit before the anticipated separation in early 2027. This appointment follows two previous executives declining the CEO role for the spinoff.
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.
Johnson & Johnson (JNJ) significantly outperformed Medtronic (MDT) over the last decade due to its strategy of spinning off businesses and reinvesting capital. However, the author suggests Medtronic could be a better investment for the next decade, as it is now adopting a similar strategy with its diabetes business, potentially unlocking shareholder value and leading to higher returns from its lower valuation and higher dividend yield.
Worldwide oral disease cases reach 3.73 billion. Listerine is launching a prevention campaign.
Kenvue's Listerine is launching a multiyear "Oral Care Counts" campaign on World Smile Day (October 2, 2026) to address the rising global oral disease cases, which now affect nearly half the world's population (3.73 billion). The initiative aims to educate consumers and healthcare professionals on the essential link between oral health and overall well-being, promoting a three-step daily routine of brushing, flossing, and rinsing. The campaign seeks to engage various stakeholders to improve understanding, access, and daily preventative habits for better oral health outcomes worldwide.
Kimberly-Clark Keeps Raising Its Dividend. The Question Is Whether It Is Keeping Up With Your Costs
Kimberly-Clark has extended its dividend increase streak to 54 years, but the most recent raise to $1.28 per share is the smallest in recent years, coinciding with a 35% drop in free cash flow. This situation, alongside a pending $48.7 billion acquisition of Kenvue, raises concerns for income investors. While competitors like Procter & Gamble and Colgate-Palmolive have seen growing cash flow, Kimberly-Clark's financial health suggests future dividend increases might remain modest to preserve the streak.
Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
Kenvue brands Neutrogena®, Aveeno®, and Regaine® are presenting 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress. The research highlights the benefits of ingredients like niacinamide, trehalose, colloidal oat, and 5% minoxidil in addressing common skin and hair concerns such as acne, hyperpigmentation, eczema, UV damage, and androgenetic alopecia, emphasizing the role of innovative formulations in improving skin barrier function and promoting hair regrowth.
Kenvue: Neutrogena, Aveeno, and Regaine Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
Kenvue brands Neutrogena, Aveeno, and Regaine presented new scientific data at the 35th European Academy of Dermatology and Venereology (EADV) Congress. The research highlights the efficacy of ingredients like niacinamide, trehalose, colloidal oat, and 5% minoxidil in addressing common skin and hair concerns, including acne, eczema, UV damage, and androgenetic alopecia. The findings reinforce the benefits of science-backed formulations for skin barrier health and hair regrowth.
Form 4 Kenvue Inc For: 29 September By Investing.com
This article reports on a Form 4 filing for Kenvue Inc. for September 29th. It is a brief announcement indicating the filing of a Form 4 for the company, published by Investing.com. The content provided is primarily metadata and boilerplate website elements, with the core information being the Form 4 filing.
Form 4 Kenvue Inc For: 29 September By Investing.com
This article announces that Kenvue Inc. filed a Form 4 for September 29th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The article itself does not provide details of the filing but merely reports its existence.
Form 4 Kenvue Inc For: 29 September By Investing.com
This article reports on the filing of Form 4 by Kenvue Inc. for the date of September 29. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) when there is a change in the beneficial ownership of a company's securities by an insider. The brief article, published on Investing.com, includes Kenvue Inc.'s stock symbol KVUE and its current percentage change.
Deferred director pay adds 1,300 stock units for Jeffrey C. Smith at Kenvue (KVUE).
Kenvue Inc. director Jeffrey C. Smith acquired 1,300 deferred share units (DSUs) on September 28, 2026, which will be settled in common shares upon his separation from service. This transaction increases his direct DSU balance to 28,618.343 units, including dividend equivalents. Smith also has an indirect beneficial ownership of 27,307,632 common shares through Starboard Value LP-managed accounts.
1,461 shares withheld for taxes on a Kenvue (KVUE) executive’s stock awards
Kenvue's Chief Operations Officer, Meredith Stevens, converted 1,461 restricted stock units into common shares on September 25, 2026. Concurrently, 1,461 common shares were withheld at $17.81 per share to cover FICA taxes, as Stevens is eligible for retirement. The transaction details were reported in a Form 4 filing, indicating direct beneficial ownership changes.
Kenvue (KVUE) director Richard E. Allison Jr. receives deferred pay in shares
Kenvue Inc. director Richard E. Allison Jr. acquired 1,300 Deferred Share Units (DSUs) on September 28, 2026, as deferred cash compensation under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU represents the right to receive one Kenvue common share, and these units will be settled upon his separation from service. Following this transaction, Allison Jr. holds a total of 51,641.767 DSUs, including those acquired as dividend equivalents.
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark (KMB) faces a significant challenge to its dividend sustainability, despite a long history of dividend raises, due to its pending $48.7 billion acquisition of Kenvue. The company's free cash flow in 2025 already fell short of its dividend payments, and its payout ratio is very high. The integration costs and debt service from the Kenvue deal could further strain KMB's finances, putting its multi-decade dividend raise streak in jeopardy for 2027.
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark (KMB) pays out almost all its earnings as dividends, with its 2025 free cash flow falling short of dividend payments. The company's impending $48.7 billion acquisition of Kenvue (KVUE) and associated integration costs and debt service are expected to strain finances, potentially threatening KMB's long-standing dividend raise streak by 2027. While the current $1.28 dividend is considered secure through the deal's closing, future increases depend on improved free cash flow and successful integration of Kenvue.
3 CPGs discuss automation, sourcing and logistics risks
At a recent Barclays conference, Procter & Gamble, Colgate-Palmolive, and Kimberly-Clark discussed their supply chain strategies and challenges. P&G is implementing "maximum automation" through its Supply Chain 3.0 initiative, while Colgate-Palmolive anticipates rising material costs due to oil prices and plans to offset them through pricing and premiumization. Kimberly-Clark expects increased logistics costs due to tight freight markets and a recent distribution center fire, and aims to reduce costs post-acquisition of Kenvue.
Kimberly-Clark Corporation (KMB) Starts Exchange Offers for Up to $7.0B Kenvue Notes
Kimberly-Clark Corporation (KMB) has initiated exchange offers and consent solicitations for up to $7.0 billion in Kenvue notes, to be exchanged for new KMB notes and cash. This move is contingent on the pending Kenvue acquisition, with an early participation deadline of October 9, 2026, and a final expiration on October 27, 2026. The exchange aims to align Kenvue's debt with Kimberly-Clark's ahead of the expected Q4 2026 closing of the acquisition, with the new KMB notes ranking pari passu with existing unsecured debt.
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
Kimberly-Clark Corporation announced the commencement of exchange offers and consent solicitations for Kenvue Inc. notes in connection with its pending acquisition of Kenvue. The offer involves exchanging Kenvue notes for up to $7 billion in new Kimberly-Clark notes and cash, with an early participation premium for holders who tender their notes by October 9, 2026. Concurrently, Kimberly-Clark is soliciting consents to amend the Kenvue Indenture to remove certain restrictive covenants, contingent upon the acquisition's completion, expected in Q4 2026.
BNP Paribas Adjusts PT on Colgate-Palmolive to $97 From $101, Keeps Outperform Rating
BNP Paribas has adjusted its price target for Colgate-Palmolive (NYSE:CL) to $97 from $101, while maintaining an "Outperform" rating on the stock. This update reflects a revised valuation for the consumer products company. The stock was trading at $86.06 with a slight gain in pre-market on September 25, 2026.
Kenvue stock rose 1.08 percent on September 25
Kenvue stock increased by 1.08 percent to USD 17.80 on September 25, 2026. The company's Q2 sales reached USD 3.955 billion, though adjusted gross margin narrowed due to inflation. Analysts maintain a "Hold" rating with an average 12-month price target of USD 19.27, while the proposed Kimberly-Clark merger faces an extended EU regulatory review until October 13.
Kenvue stock at USD 17.80 on September 25, 2026
Kenvue stock closed at USD 17.80 on September 25, 2026, marking a 1.08 percent increase from its previous close. The company announced a quarterly dividend of USD 0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026. The stock, traded on the New York Stock Exchange under the ticker KVUE, saw a daily change of USD 0.19.
Kenvue Inc. stock rises Friday, outperforms market
Kenvue Inc. (KVUE) stock rose 1.08% on Friday, closing at $17.80 and breaking a two-day losing streak. This performance outpaced the broader market, with the S&P 500 Index rising 0.51% and the Dow Jones Industrial Average gaining 0.93%.
Kenvue stock slips 1.06 percent ahead of the open
Kenvue stock (US49177J1025) closed at USD 17.67 on September 24, 2026, marking a 1.06 percent decline on the NYSE, underperforming the S&P 500. Trading volume was over 16 million shares, with the stock 12.23 percent below its 52-week high and 26.03 percent above its 52-week low. Recent news includes a significant share purchase by Andra AP fonden and ongoing discussions regarding a potential Kimberly-Clark transaction.
Kenvue stock trades 11.9 percent below its yearly high
Kenvue stock is trading 11.9% below its 52-week high after reporting Q2 2026 sales of $3.955 billion and adjusted EPS of $0.31, missing the $0.32 consensus. The European Commission has extended its decision deadline for a proposed transaction to October 13, 2026, shifting the focus to regulatory clearance. The company also declared a $0.21 quarterly dividend payable on October 2.
Andra AP fonden Acquires Shares of 210,900 Kenvue Inc. $KVUE
Andra AP fonden has acquired 210,900 shares of Kenvue Inc. (NYSE:KVUE) worth approximately $4.03 million in the second quarter, making it a new position for the fund. Other institutional investors like HBK Investments L.P., Tidal Investments LLC, and National Pension Service also increased their stakes. Kenvue, which reported Q2 revenue of $3.96 billion (up 3% year-over-year) and a slightly missed EPS of $0.31, maintains a consensus "Hold" rating from analysts with an average price target of $19.27.
EU extends review of Kimberly-Clark’s $40B Kenvue deal
The European Union has extended its review of Kimberly-Clark's $40 billion acquisition of Kenvue after Kimberly-Clark offered concessions to address antitrust concerns. The European Commission moved its decision deadline to October 13 from September 29 and will now seek feedback on the proposed remedies. Kimberly-Clark is reportedly prepared to sell assets to secure approval, while the deal has already received conditional clearance in other markets like Australia.
Kenvue stock rises as Kimberly Clark advances its takeover bid
Kenvue stock saw a 1.10 percent increase following progress in Kimberly Clark's proposed $40 billion takeover bid, with concessions offered to address EU antitrust concerns. The European Commission has set a provisional October 13 deadline for its decision. Kenvue's Q2 FY26 revenue was reported at $3.96 billion and earnings at $456 million, with the stock closing at $17.86, still below analyst target estimates.
kimberly clark offers eu remedies for 40 billion kenvue deal
Kimberly-Clark has offered concessions to the European Union to address antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission has extended its review deadline to October 13 to assess the proposed remedies, which may include asset divestitures. This follows conditional approval in Australia and South Africa, with Australia requiring the divestment of Kenvue’s Carefree and Stayfree brands.
Activist Toms Capital urges Devon Energy in letter to explore alternatives, including a sale
Activist hedge fund Toms Capital Management has sent a letter to Devon Energy, urging the Houston-based oil and gas company to explore strategic alternatives, including a sale. Toms, now a top-five shareholder with over $4 billion in assets, believes the company's portfolio of properties, including those from its merger with Coterra Energy, creates undue complexity and a valuation discount. The fund is joined by litigator Alex Spiro in its campaign, advocating for a sale to a strategic buyer who could then divest assets, shifting execution risk from Devon shareholders.
Nykredit A S Acquires Shares of 235,332 Kenvue Inc. $KVUE
Nykredit A/S has acquired a new stake of 235,332 shares in Kenvue Inc. (NYSE:KVUE) during the second quarter, valued at approximately $4.5 million. Institutional investors now own 97.64% of the company. Kenvue reported quarterly revenue of $3.96 billion, a 3% year-over-year increase, but missed earnings estimates, and maintains a consensus "Hold" rating from analysts with an average price target of $19.27.
Kenvue stock adds 1.1 percent ahead of the open
Kenvue stock saw a 1.1 percent gain, closing at USD 17.86 on September 22, 2026, outperforming the Nasdaq Composite. The company's shares traded ex-dividend on September 21, 2026, with a USD 0.21 per share quarterly cash dividend scheduled for payment on October 2, 2026.
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
Johnson & Johnson is reportedly considering selling its orthopedics unit, DePuy Synthes, for $20 billion, with Apollo Global Management as a potential buyer. This move follows the spin-off of Kenvue in 2023 and aligns with J&J's strategy to streamline operations and focus on higher-growth, higher-margin healthcare businesses. The sale would allow J&J to simplify its structure, free up capital, and accelerate its shift towards a leaner, more profitable company.
Colgate-Palmolive (NYSE:CL) Stock Price
This article provides an overview of Colgate-Palmolive (NYSE:CL) stock, highlighting its current market valuation, recent price performance, and analyst fair values. It details the company's financial health, including revenue, gross profit, and earnings, and describes its operating segments (Oral, Personal and Home Care; Pet Nutrition). The article also mentions recent news such as dividend announcements and updates on strategic narratives focusing on cost optimization and premium product mix.
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
Johnson & Johnson (JNJ) is reportedly considering selling its DePuy Synthes orthopedics unit to Apollo Global Management for $20 billion, following its 2023 spin-off of Kenvue. This move aligns with J&J's strategy to streamline operations, focus on higher-margin, faster-growing healthcare segments, and become a leaner, more profitable company. For investors, this signals a commitment to increased profitability and accelerated growth, potentially rewarding J&J shareholders.
Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer
This article compares the dividend safety of Clorox (CLX) and Kimberly-Clark (KMB), both household staples companies with long histories of dividend raises. While Clorox offers a higher current yield, its dividend coverage is stressed, with management acknowledging it as "elevated." Kimberly-Clark, despite a slightly lower yield, demonstrates superior dividend safety due to stronger cash flow coverage, a robust balance sheet, and a longer streak of consecutive dividend increases, making it the safer choice for retirement-focused investors.
Engineers Gate Manager LP Reduces Stock Position in Kenvue Inc. $KVUE
Engineers Gate Manager LP significantly reduced its stake in Kenvue Inc. (NYSE:KVUE) by 88.9% in the second quarter, selling 391,714 shares and holding 49,084 shares valued at $938,000. Other institutional investors showed mixed activity, with some increasing and others decreasing their positions in KVUE. The article also notes recent analyst ratings, Kenvue's financial performance, and its upcoming dividend payment.
Former J&J Unit Beats Claims Its Sunscreen Caused Cancer
A Philadelphia jury has found Kenvue, formerly Johnson & Johnson Consumer Inc., not liable in lawsuits alleging its aerosol sunscreen caused cancer deaths. The lawsuits were brought by the estates of two women who died from cancer.
Kimberly Clark (KMB) Lines Up Assets for $40 Billion Deal Review
Kimberly-Clark (KMB) plans to sell assets to address European Union antitrust concerns related to its proposed $40 billion acquisition of Kenvue. This move is part of Kimberly-Clark's strategy to transform into a higher-margin consumer-health and hygiene powerhouse, similar to Procter & Gamble and Colgate-Palmolive. The asset sales aim to mitigate competitive overlap and keep the deal on track, although it introduces execution risks associated with a more concentrated portfolio.
BNP Paribas Adjusts Price Target on Kimberly-Clark to $101 From $111, Keeps Neutral Rating
BNP Paribas has adjusted its price target for Kimberly-Clark (KMB) shares, lowering it from $111 to $101, while maintaining a Neutral rating on the stock. This update comes amidst other analyst adjustments and ongoing news regarding Kimberly-Clark's potential asset sales to secure EU approval for its acquisition of Kenvue. The company's stock information and recent news highlight analyst activity and acquisition-related developments.
Kenvue Inc. $KVUE Shares Sold by Corient Private Wealth LP
Corient Private Wealth LP has reduced its stake in Kenvue Inc. by 26.5% during the second quarter, selling 146,133 shares. Despite this, other hedge funds, including BlackRock Inc. and Pentwater Capital Management LP, have acquired significant new positions in Kenvue. The company recently reported its quarterly earnings, missing analyst estimates slightly, and declared a quarterly dividend of $0.21 per share.
Canaccord Genuity Keeps Their Buy Rating on Kenvue, Inc. (KVUE)
Canaccord Genuity analyst Susan Anderson has reiterated a Buy rating on Kenvue, Inc. (KVUE). Despite the analyst consensus being a Hold with an average price target of $19.25, Kenvue recently reported strong quarterly revenues of $3.96 billion and a net profit of $456 million, showing an increase from the previous year.
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
This article compares Johnson & Johnson (JNJ) and Kenvue (KVUE) as potential dividend king investments. While J&J boasts 64 consecutive dividend increases and focuses on high-growth areas, it faces significant legal liabilities from talc-related lawsuits. Kenvue offers a higher yield, but its pending acquisition by Kimberly-Clark introduces uncertainty regarding its future as a standalone dividend stock. The author concludes that J&J is the better buy-and-hold option due to its stable dividend history and diverse business model, despite its legal challenges.
Neutrogena® launches new sunscreen technology with Cloud-Tech™ - A new view of care
Neutrogena has launched Cloud-Tech™, a new sunscreen technology featuring bemotrizinol (BEMT), the first new FDA-approved sunscreen filter in over 25 years. This innovation aims to provide comprehensive UVA/UVB coverage with a weightless, K-beauty inspired feel, addressing consumer demand for stronger protection and a better product experience. The technology is integrated into two new products, Neutrogena® Clear Face Sunscreen SPF 60 and Neutrogena® Ultra Sheer Daily Face Sunscreen SPF 70, which also include clinically proven skincare ingredients like Micro-Peptide Technology and niacinamide.
